Engineered immune cells take aim at chest cancer

NCT ID NCT02414269

First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 21 times

Summary

This study tests a treatment using a patient's own immune cells (T cells) that are modified in a lab to attack cancer cells with a protein called mesothelin. It is for people with malignant pleural disease, including mesothelioma and cancers that have spread to the chest lining. The first part finds a safe dose, and the second part combines it with another drug (pembrolizumab) to see if it helps control the cancer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Memorial Sloan Kettering Basking Ridge (Consent and Follow-Up)

    Basking Ridge, New Jersey, United States

  • Memorial Sloan Kettering Bergen (Consent and Follow-Up)

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center (Consent and Follow-Up)

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Consent and Follow-Up)

    Commack, New York, United States

  • Memorial Sloan Kettering Monmouth (Consent and Follow-Up)

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Westchester (Consent and Follow-Up)

    Harrison, New York, 10604, United States

Conditions

Explore the condition pages connected to this study.